Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Michael ZhongAnneke Van Der WaltJim StankovichTomas KalincikKatherine BuzzardOlga SkibinaCavit BozSuzanne HodgkinsonMark SleeJeannette Lechner-ScottRichard MacdonellJulie PrevostJens KuhleGuy LaureysLiesbeth Van HijfteRaed AlroughaniAllan G KermodeErnest ButlerMichael Harry BarnettSara EichauVincent van PeschPierre GrammondPamela McCombeRana KarabudakPierre DuquetteMarc GirardBruce TaylorWei YehMastura MonifMelissa GresleHelmut ButzkuevenVilija G JokubaitisPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
The risk of disability worsening during switch to ocrelizumab is reduced by short treatment gaps. Patients who cease fingolimod are at heightened relapse risk in the first 3 months on ocrelizumab. Prospective evaluation of strategies such as washout reduction may help optimise this switch.